Shrinivas Bishu, MD
Enriched profileAssistant Professor, University of Michigan · University of Michigan
Shrinivas Bishu is Assistant Professor, University of Michigan at University of Michigan. OpenAlex indexes 231 publications with 3,815 citations (h-index 32); ClinicalTrials.gov lists 1 registered study with this person as an investigator.
Data verified 18 Oct 2026
Overview
Updated 18 Oct 2026
Shrinivas Bishu, M.D., is Assistant Professor, University of Michigan. The public record shows 231 publications with 3,815 citations (h-index 32), centered on Inflammatory Bowel Disease, Ocular Diseases and Behçet’s Syndrome, Gut microbiota and health. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 7 companies, 1 NIH-funded awards (2020–2024).
- Most recent indexed publication: 2026 · Inflammatory bowel diseases
- Top research focus: Inflammatory Bowel Disease
- 1 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 52.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:
- Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease
Sponsor: University of Michigan
Industry payments
Updated 18 Oct 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202514 payments$18,248openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year20253 payments
- Janssen Global Services, LLCProgram year202412 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57%JAK inhibitor17.3%Xeljanz54%Rinvoq46%Part D<11 patientsInterleukin-12 Antagonist17.3%Stelara100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
35.5%Proton pump inhibitor22%Omeprazole68%Pantoprazole Sodium32%Part D<11 patientsAminosalicylate13.6%Mesalamine59%Balsalazide Disodium41%Part D<11 patientsBlood & clotting
7.5%Solutions for parenteral nutrition7.5%Peg 3350-Electrolyte100%Part D≥16 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 18 Oct 2026
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
- CD4+ Tissue resident memory T-cells in Crohnâs Disease
University of Michigan at Ann Arbor
FY2024$169,560K08DK123403 - CD4+ Tissue resident memory T-cells in Crohnâs Disease
University of Michigan at Ann Arbor
FY2023$169,560K08DK123403 - CD4+ Tissue resident memory T-cells in Crohn's Disease
University of Michigan at Ann Arbor
FY2022$169,127K08DK123403
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The right dose for the right patient: Toward precision infliximab therapy in acute severe ulcerative colitis.
Inflammatory bowel diseases
Comment2026 - Navigating Treatment Selection in Acute Severe Ulcerative Colitis: A Prospective Mixed Method Analysis of Factors Influencing Patient Decision-Making.
Digestive diseases and sciences
Article2026 - Editorial: Upadacitinib in Perianal Crohn's Disease.
Alimentary pharmacology & therapeutics
Editorial2026 - Rethinking the dose: A Bayesian meta-analysis of infliximab intensification in acute severe ulcerative colitis.
Inflammatory bowel diseases
Meta-analysis2026 - Review Article: TL1A Inhibitors in IBD - Mechanistic Rationale and Clinical Evidence.
Alimentary pharmacology & therapeutics
Review2026
Most-cited works
by citation count (OpenAlex)Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/shrinivas-bishu-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Other
prereview.org/profiles/0000-0003-4823-5805
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →prereview.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Nebraska Medical Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uofmhealth.org ↗ - Bachelor's degree
University of Pennsylvania
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uofmhealth.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medresearch.umich.edu ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medifind.com ↗
Secondary affiliations
appointments beyond the home institution- Clinical Director of IBD
Crohn's & Colitis Center, University of Michigan
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medifind.com ↗ - Associate Program Director
GI Fellowship, University of Michigan
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medifind.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
Eva Feldman, MD
University of Michigan
Matthias Kretzler, MD
University of Michigan
Charles Rice, MD
The Rockefeller University
Edward Loftus, MD
Mayo Clinic Rochester
Naga Chalasani, MD
Indiana University School of Medicine
Bruce Sands, MD
Icahn School of Medicine at Mount Sinai